Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
| Author List |
|---|
| Kimberly Struble |
| Kirk Chan-Tack |
| Karen Qi |
| Thamban Valappil |
| Sarah Connelly |
| Poonam Mishra |
| Dionne Price |
| Jeffrey Murray |
| Debra Birnkrant |
Abstract
Under representation of black subjects in trials of hepatitis C virus (HC V) direct-acting antivirals (DAA s) complicates assessment of differential outcomes for black individuals vs non-black individuals. HC V trials submitted to the Food and Drug Administration (2013–2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HC V genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity.
Published
Article Category
Hepatitis C (HCV)
Article Type
Original research
Posted Date
19-09-2019
